These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12914621)

  • 1. Study of precursors of ventricular tachycardia from data stored in the memory of a dual chamber implantable cardioverter defibrillator.
    Leenhardt A; Sadoul N; Mabo P; Kacet S; Lavergne T; Saoudi N; Iscolo N;
    Pacing Clin Electrophysiol; 2003 Jul; 26(7 Pt 1):1454-60. PubMed ID: 12914621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RR interval analysis based on a newly developed PC program as a predictor of interventions in implantable cardioverter-defibrillator patients.
    Lewandowski M; Kowalik I
    Adv Clin Exp Med; 2021 Mar; 30(3):279-288. PubMed ID: 33754502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of ventricular ectopic beats in short-term RR interval recordings to predict imminent ventricular tachyarrhythmia.
    Martínez-Alanis M; Ruiz-Velasco S; Lerma C
    Int J Cardiol; 2016 Dec; 225():226-233. PubMed ID: 27732926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up.
    Schläpfer J; Rapp F; Kappenberger L; Fromer M
    J Am Coll Cardiol; 2002 Jun; 39(11):1813-9. PubMed ID: 12039497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiation of monomorphic ventricular tachycardia: electrophysiological, clinical features, and drug therapy in patients with implantable defibrillators.
    Gorenek B; Kudaiberdieva G; Birdane A; Goktekin O; Cavusoglu Y; Bakar S; Unalir A; Ata N; Timuralp B
    J Electrocardiol; 2003 Jul; 36(3):213-8. PubMed ID: 12942483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms.
    Theuns DA; Klootwijk AP; Goedhart DM; Jordaens LJ
    J Am Coll Cardiol; 2004 Dec; 44(12):2362-7. PubMed ID: 15607399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.
    Domanski MJ; Sakseena S; Epstein AE; Hallstrom AP; Brodsky MA; Kim S; Lancaster S; Schron E
    J Am Coll Cardiol; 1999 Oct; 34(4):1090-5. PubMed ID: 10520795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
    N Engl J Med; 1997 Nov; 337(22):1576-83. PubMed ID: 9411221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A; Sapp J
    Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian pattern of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Wood MA; Simpson PM; London WB; Stambler BS; Herre JM; Bernstein RC; Ellenbogen KA
    J Am Coll Cardiol; 1995 Mar; 25(4):901-7. PubMed ID: 7884095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
    Wilkoff BL; Cook JR; Epstein AE; Greene HL; Hallstrom AP; Hsia H; Kutalek SP; Sharma A;
    JAMA; 2002 Dec; 288(24):3115-23. PubMed ID: 12495391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporary disturbances of the QT interval precede the onset of ventricular tachyarrhythmias in patients with structural heart diseases.
    Diem BH; Stellbrink C; Michel M; Schauerte P; Hanrath P
    Pacing Clin Electrophysiol; 2002 Oct; 25(10):1413-8. PubMed ID: 12418736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiodarone decreases plasma brain natriuretic peptide level in patients with heart failure and ventricular tachyarrhythmia.
    Shiga T; Hosaka F; Wakaumi M; Matsuda N; Tanizaki K; Kajimoto K; Shoda M; Hagiwara N; Kasanuki H
    Cardiovasc Drugs Ther; 2003 Jul; 17(4):325-33. PubMed ID: 14618094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators.
    Hallstrom AP; McAnulty JH; Wilkoff BL; Follmann D; Raitt MH; Carlson MD; Gillis AM; Shih HT; Powell JL; Duff H; Halperin BD;
    J Am Coll Cardiol; 2001 Mar; 37(4):1093-9. PubMed ID: 11263614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.
    de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J
    Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator.
    Gao D; Van Herendael H; Alshengeiti L; Dorian P; Mangat I; Korley V; Ahmad K; Golovchiner G; Aves T; Pinter A
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):199-204. PubMed ID: 23609328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias.
    Ricci R; Pignalberi C; Disertori M; Capucci A; Padeletti L; Botto G; Toscano S; Miraglia F; Grammatico A; Santini M
    Eur Heart J; 2002 Sep; 23(18):1471-9. PubMed ID: 12208228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.